Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Hepatitis C, Chronic

Drug Information

Target Indication

Hepatitis C, Chronic

Clinical Trial

Last updated: 8/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Related Pipeline

Heart Failure

Hepatitis C, Chronic

Hepatitis C

Rotavirus Gastroenteritis

HIV-1 Infection

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts